Inflitza 25mg Capsule

About Inflitza 25mg Capsule

Inflitza 25mg Capsule contains Midostaurin, a multi-targeted kinase inhibitor used in the treatment of specific types of cancers, particularly acute myeloid leukemia (AML) and advanced systemic mastocytosis (ASM). Midostaurin functions by inhibiting several kinases that are essential for the development and spread of cancer cells.

Notify your doctor of any illnesses or drugs you are taking, refrain from using them while pregnant or nursing, and make sure you are using effective contraception while undergoing treatment.

Brand Name: Inflitza

Composition: Midostaurin

Mechanism of Action:

Some malignancies have overactive receptor tyrosine kinases, such as FLT3 (FMS-like tyrosine kinase, KIT, and others, which are inhibited by the targeted medication midostaurin. It primarily targets FLT3 mutations, which are responsible for the leukemia cells' fast growth and proliferation in acute myeloid leukemia (AML). It inhibits KIT signaling in systemic mastocytosis, which lowers aberrant mast cell growth and relieves related symptoms. Because of its dual activity, midostaurin effectively treats various disorders by directly disrupting the molecular pathways that drive the course of the disease.

Uses:

• Acute Myeloid Leukemia
• Advanced Systemic Mastocytosis

Dosage and Administration:

50 mg twice a day, or every 12 hours, when receiving chemotherapy. In order to increase absorption and lessen gastrointestinal adverse effects, capsules should be taken with food.

Side Effects:

• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Headache
• Fever
• Muscle and joint pain
• Rash